Which company does Adagrasib come from?

Adagrasib (Adagrasib) was discovered by the well-known Mirati Therapeutics (also known as Bristol-Myers Squibb). It has made significant progress in clinical trials for patients with KRAS G12C mutated non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and other solid tumors. Especially in the Phase 1/2 clinical trial of Krystal-1, the therapeutic effect of adagrasib has attracted much attention.

Adagarasib belongs to theRAS GTPase family and is an antineoplastic agent formulated as film-coated tablets for the oral route of administration. Adagarasib is indicated for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with a KRAS G12C mutation. The exposure-response relationship and pharmacodynamic response time course of adagrasib have not been elucidated. Use of adagrasib may result in prolongation of the QTc interval. The increase in QTc is concentration dependent. In patients administered adagrasiib 600 mg twice daily, the mean QTcF change from baseline (QTcF) was 18 ms at the mean steady-state maximum concentration. Use of adagrasib may also result in serious gastrointestinal adverse effects, hepatotoxicity, and interstitial lung disease/pneumonitis.

Bristol-Myers Squibb is conducting clinical development of adagrasib, which is currently in Phase III treatment for metastatic colorectal cancer. According to GlobalData, the Phase III drug for the treatment of metastatic colorectal cancer has a PTSR indication benchmark of 49% and can enter the pre-registration stage. GlobalData's report evaluates how drug-specific PTSR and Likelihood of Approval (LoA) scores for adagrasiib compare to indication benchmarks.